Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
OBJECTIVE
To determine the relationship between maternal antiretroviral regimens during pregnancy and adverse infant outcomes [low birth weight (LBW) and preterm birth]. The a priori hypothesis was that protease inhibitor (PI)-containing regimens are associated with an increased risk of LBW and preterm birth.


METHODS
Prospective cohort study of HIV-1-infected women and their infants (NISDI Perinatal Study).


METHODS
Data were analysed from 681 women receiving at least one antiretroviral drug [in order of increasing complexity: one or two nucleoside reverse transcriptase inhibitors (1-2 NRTI), two NRTI plus one non-nucleoside reverse transcriptase inhibitor (NNRTI) (HAART/NNRTI), or two NRTI plus one PI (HAART/PI)] for at least 28 days during pregnancy, and who delivered live born, singleton infants with known birth weight and gestational age by 1 March 2005. Multivariable logistic regression modeling was used to assess the relationship of maternal ART with LBW and with preterm birth, adjusting for covariates.


RESULTS
The incidence of LBW and preterm birth, respectively, was 9.6% and 7.4% (1-2 NRTI), 7.4% and 5.8% (HAART/NNRTI), and 16.7% and 10.6% (HAART/PI). There was no statistically significant increased risk of LBW [adjusted odds ratio (AOR), 1.5; 95% confidence interval (95% CI), 0.7-3.2] or preterm birth (AOR, 1.1; 95% CI, 0.5-2.8) among women who received HAART/PI compared with women receiving 1-2 NRTI.


CONCLUSIONS
Among a population of HIV-1-infected women in Latin America and the Caribbean, maternal receipt of PI-containing ART regimens during pregnancy was not associated with a statistically significant increase in risk of LBW or preterm birth.
Szyld
Edgardo G
EG
Hosp Diego Paroissien, Brazil. ezyld@fibertel.com.ar
Warley
Eduardo M
EM
Freimanis
Laura
L
Gonin
René
R
Cahn
Pedro E
PE
Calvet
Guilherme A
GA
Duarte
Geraldo
G
Melo
Victor H
VH
Read
Jennifer S
JS
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001118:Argentina / Q000453:epidemiology; D001444:Bahamas / Q000453:epidemiology; D001938:Brazil / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D008800:Mexico / Q000453:epidemiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000453:epidemiology; D011256:Pregnancy Outcome; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors